Shots:

• Remix to receive $45M as up front and research funding in cash & is eligible to receive preclinical/clinical, commercial, and sales milestones with a total deal value of ~$1B along with royalties for any resulting products
• Janssen obtains exclusive rights to three specific targets with applications in immunology and oncology. Additionally, Remix will have the opportunity to opt into a portion of the costs on one program for clinical development
• The collaboration will utilize Remix’s REMaster drug discovery platform to develop small molecule therapeutics that modulate RNA processing and will also provide additional resources for new products

 Ref: PR Newswire | Image: PR Newswire